Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Serum-stimulated 2 receptor (ST2), also known as IL1RL1, is a member of the interleukin-1 receptor family. It exists in two main forms: a transmembrane receptor (ST2L) and a soluble form (sST2). ST2L binds to interleukin-33 (IL-33), triggering downstream signaling pathways involved in immune responses and cardioprotection. sST2 acts as a decoy receptor, modulating IL-33 availability. sST2 is a biomarker for heart failure.
sST2 acts as a decoy receptor, binding IL-33 and preventing its interaction with the membrane-bound ST2L receptor.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Serum-stimulated 2 receptor (ST2).